中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 11
Nov.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(11): 2201-2204

Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous direct-acting antiviral agent failure

DOI: 10.12449/JCH241112
  • 1.

    Department of Hepatology，Nanjing Second Hospital，Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine，Nanjing 210003，China

  • 2.

    Department of Hepatology，Wuxi Fifth People’s Hospital，Wuxi，Jiangsu 214011，China

  • 3.

    Department of Hepatology，The Third People’s Hospital of Zhenjiang，Zhenjiang，Jiangsu 212021，China

More Information
  • Corresponding author: CHANG Jiabao， chang_jiabao@126.com （ORCID： 0000-0003-3209-4868）
  • Received Date: 2024-02-22
  • Accepted Date: 2024-04-16
  • Published Date: 2024-11-25
    Abstract
  •   Objective  To investigate the efficacy and safety of sofosbuvir/velpatasivr/voxilaprevir （SOF/VEL/VOX） in patients with HCV infection experiencing failure in previous direct-acting antiviral agent （DAA） therapy.  Methods  A retrospective analysis was performed for the chronic hepatitis C patients who experienced failure in previous DAA antiviral therapy and were treated with SOF/VEL/VOX （400 mg/100 mg/100 mg/tablet， 1 tablet/day） for 12 weeks in Nanjing Second Hospital， Wuxi Fifth People’s Hospital， and The Third People’s Hospital of Zhenjiang from June 2020 to June 2023. Sustained virological response at 12 weeks （SVR12） was observed after the end of treatment， and the changes in biochemical parameters and the incidence rate of adverse reactions were assessed to evaluate drug safety. The paired t-test was used for comparison of continuous data between two groups.  Results  A total of 36 patients were enrolled， among whom there were 27 non-liver cirrhosis patients and 9 patients with compensated liver cirrhosis， and 4 patients experienced failure in the previous two or more sessions of DAA therapy. Two patients were lost to follow-up after treatment， and the remaining 34 patients （34/36， 94.4%） achieved SVR12. Among the 36 patients enrolled， the most common adverse events were pruritus， nausea， fatigue， and headache， and one patient （2.78%） experienced serious adverse events； there were no adverse events that resulted in the discontinuation of therapeutic agents or the death of patients.  Conclusion  For chronic hepatitis C patients who experience failure in previous DAA therapy， SOF/VEL/VOX salvage therapy has a relatively high rate of SVR12， with good tolerability and safety.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study[J]. Lancet Gastroenterol Hepatol, 2022, 7( 5): 396- 415. DOI: 10.1016/S2468-1253(21)00472-6.
    [2]
    MANGIA A, MILLIGAN S, KHALILI M, et al. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts[J]. Liver Int, 2020, 40( 8): 1841- 1852. DOI: 10.1111/liv.14537.
    [3]
    XIAO L, ZHANG LY. Efficacy and safety of elbasvir/grazoprevir treatment for Chinese patients with hepatitis C virus genotype 1b[J]. Int J Virol, 2023, 30( 5): 423- 428. DOI: 10.3760/cma.j.issn.1673-4092.2023.05.017.

    肖琳, 张岭漪. 艾尔巴韦/格拉瑞韦治疗中国1b型慢性丙型肝炎患者的疗效和安全性[J]. 国际病毒学杂志, 2023, 30( 5): 423- 428. DOI: 10.3760/cma.j.issn.1673-4092.2023.05.017.
    [4]
    BOURLIÈRE M, GORDON SC, FLAMM SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection[J]. N Engl J Med, 2017, 376( 22): 2134- 2146. DOI: 10.1056/NEJMoa1613512.
    [5]
    Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline for the prevention and treatment of hepatitis C(2022 version)[J]. Chin J Clin Infect Dis, 2022, 15( 6): 428- 447. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022, 15( 6): 428- 447. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002.
    [6]
    European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series[J]. J Hepatol, 2020, 73( 5): 1170- 1218. DOI: 10.1016/j.jhep.2020.08.018.
    [7]
    RAO HY. Key points in hepatitis C guidance 2023 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection[J]. J Clin Hepatol, 2023, 39( 12): 2798- 2803. DOI: 10.3969/j.issn.1001-5256.2023.12.008.

    饶慧瑛.《美国肝病学会/美国感染病学会丙型肝炎指导意见: HCV感染的检测、管理和治疗(2023年更新)》意见要点[J]. 临床肝胆病杂志, 2023, 39( 12): 2798- 2803. DOI: 10.3969/j.issn.1001-5256.2023.12.008.
    [8]
    JI FP, LI J, LIU L, et al. High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b[J]. J Gastroenterol Hepatol, 2021, 36( 3): 767- 774. DOI: 10.1111/jgh.15192.
    [9]
    CHEN CY, HUANG CF, CHENG PN, et al. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan[J]. Liver Int, 2021, 41( 6): 1265- 1277. DOI: 10.1111/liv.14849.
    [10]
    MENDIZABAL M, PINERO F, RIDRUEJO E, et al. Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents[J]. Clin Gastroenterol Hepatol, 2020, 18( 11): 2554- 2563. e 3. DOI: 10.1016/j.cgh.2020.02.044.
    [11]
    CARRAT F, FONTAINE H, DORIVAL C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: A prospective cohort study[J]. Lancet, 2019, 393( 10179): 1453- 1464. DOI: 10.1016/S0140-6736(18)32111-1.
    [12]
    BACKUS LI, BELPERIO PS, SHAHOUMIAN TA, et al. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease[J]. Hepatology, 2019, 69( 2): 487- 497. DOI: 10.1002/hep.29408.
    [13]
    HONG CM, LIN YY, LIU CJ, et al. Drug resistance profile and clinical features for hepatitis C patients experiencing DAA failure in Taiwan[J]. Viruses, 2021, 13( 11): 2294. DOI: 10.3390/v13112294.
    [14]
    BELPERIO PS, SHAHOUMIAN TA, LOOMIS TP, et al. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients[J]. J Viral Hepat, 2019, 26( 8): 980- 990. DOI: 10.1111/jvh.13115.
    [15]
    PAPALUCA T, ROBERTS SK, STRASSER SI, et al. Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus(HCV) NS5A-inhibitor experienced patients with difficult to cure characteristics[J]. Clin Infect Dis, 2021, 73( 9): e3288- e3295. DOI: 10.1093/cid/ciaa1318.
    [16]
    LLANERAS J, RIVEIRO-BARCIELA M, LENS S, et al. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs[J]. J Hepatol, 2019, 71( 4): 666- 672. DOI: 10.1016/j.jhep.2019.06.002.
    [17]
    WILSON E, COVERT E, HOFFMANN J, et al. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV(RESOLVE STUDY)[J]. J Hepatol, 2019, 71( 3): 498- 504. DOI: 10.1016/j.jhep.2019.05.021.
    [18]
    CHEN SS, YAN R, ZHOU K, et al. Efficacy of SOF/VEL/VOX retreatment in DAAs-failed chronic hepatitis C patients with different genotypes[J]. Chin J Clin Infect Dis, 2023, 16( 5): 372- 376. DOI: 10.3760/cma.j.issn.1674-2397.2023.05.006.

    陈闪闪, 严蓉, 周克, 等. 索磷布韦/维帕他韦/伏西瑞韦再治疗DAAs治疗失败的不同基因型慢性丙型肝炎患者的疗效分析[J]. 中华临床感染病杂志, 2023, 16( 5): 372- 376. DOI: 10.3760/cma.j.issn.1674-2397.2023.05.006.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (105) PDF downloads(32) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return